)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nanologica
Nanologica (NICA) investor relations material
Nanologica Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary31 Aug, 2026
Executive summary
Net sales for Q2 2026 reached SEK 24.3 million, a significant increase from SEK 2.3 million year-over-year, mainly due to the consolidation of Syntagon.
Operating profit for Q2 was SEK -18.1 million (Q2 2025: SEK -11.3 million); for H1, operating profit was SEK 49.0 million, positively impacted by SEK 75.7 million in negative goodwill from the Syntagon acquisition.
Syntagon contributed SEK 22.8 million to Q2 net sales, while Nanologica contributed SEK 2.5 million.
The integration of Syntagon and expansion of the sales organization were key operational focuses.
Financial highlights
Net sales for H1 2026 were SEK 45.8 million (H1 2025: SEK 13.1 million).
Profit before tax for Q2 was SEK -18.7 million (Q2 2025: SEK -12.8 million); for H1, SEK 47.1 million (H1 2025: SEK -23.0 million).
Earnings per share for Q2 were SEK -0.06 (Q2 2025: SEK -0.15); for H1, SEK 0.66 (H1 2025: SEK -0.28).
Cash and cash equivalents at June 30, 2026, were SEK 19.1 million (June 30, 2025: SEK 26.4 million).
Equity at period end was SEK 156.4 million (June 30, 2025: SEK 51.1 million).
Outlook and guidance
Priorities for H2 2026 include increasing Syntagon’s sales and profitability and converting Nanologica’s customer pipeline into commercial orders.
Large-scale silica production is now stable, supporting future commercialization and sales growth.
The company expects continued sales growth in chromatography products and contract manufacturing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nanologica
- Strong sales growth and profitability driven by Syntagon acquisition and capital measures.NICA
Q1 2026 - Acquisition and capital raise set stage for accelerated growth and improved profitability in 2026.NICAQ4 2025
- Sales surged and losses narrowed as stable production enabled new market orders and product launches.NICAQ3 2025
- Sales grew in H1, but Q2 losses deepened; production gains and new orders signal optimism.NICAQ2 2025
- Sales growth and new orders offset by deepening losses and major asset write-downs.NICAQ3 2024
- Strong sales growth and narrowed losses position Nanologica for ambitious 2024 targets.NICAQ2 2024
- Record sales and narrowed losses set the stage for strong growth in 2025.NICAQ1 2025
- Record sales and improved liquidity set the stage for Nanologica's growth in chromatography.NICAQ4 2024
Next Nanologica earnings date
Q3 202626 Nov, 2026
Nanologica
Next Nanologica earnings date
Q3 202626 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nanologica AB, a nanotechnology company, develops nanoporous silica for applications in the life science industry. Its technology combines a biologically active component with nano-sized pores to improve the delivery of drugs and vaccines to the target via controlled release mechanisms. The company’s products include Nano-pillars and Nano-spheres that are used in various applications such as biological treatments, diagnostics, or therapeutic medicines, as well as drug formulations in pharmaceuticals and other industries. Nanologica AB was founded in 2004 and is based in Södertälje, Sweden.